O. Cil

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “351 Selective isoxazolopyrimidine SLC26A6 inhibitors for treatment of cystic fibrosis–associated intestinal disorders”.

351 Selective isoxazolopyrimidine SLC26A6 inhibitors for treatment of cystic fibrosis–associated intestinal disorders

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01278-x

N/A

0DataRank · unranked

0 citations

LancasterBarbosa Goncalves, Jagriti Karmakar, O. Cil, T. Ming Chu

352 SLC26A3 (downregulated in adenoma) inhibitors with extracellular site of action block intestinal fluid absorption and reduce constipation in mice

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01279-1

N/A

0DataRank · unranked

0 citations

Joy Karmakar, Marc O. Anderson, O. Cil, Lívia de Souza Gonçalves

175 Nanomolar potency 3-carboxy-2-methylbenzofuran pendrin inhibitors for treatment of cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01106-2

N/A

0DataRank · unranked

0 citations

Lívia de Souza Gonçalves, Joy Karmakar, Marc O. Anderson, O. Cil, Ryan G. Master